The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 14, 2023

Filed:

Oct. 31, 2016
Applicant:

Imperial College Innovations Limited, London, GB;

Inventors:

Amin Hajitou, London, GB;

Paladd Asavarut, London, GB;

Teerapong Yata, London, GB;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/864 (2006.01); C12N 15/86 (2006.01); A61K 48/00 (2006.01); A61K 31/53 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/86 (2013.01); A61K 31/53 (2013.01); A61K 48/00 (2013.01); A61K 39/00 (2013.01); A61K 2039/5256 (2013.01); C12N 2750/14134 (2013.01); C12N 2750/14143 (2013.01); C12N 2750/14144 (2013.01); C12N 2750/14152 (2013.01); C12N 2795/00043 (2013.01); C12N 2795/00044 (2013.01); C12N 2795/00045 (2013.01); C12N 2795/14134 (2013.01); C12N 2795/14143 (2013.01); C12N 2795/14144 (2013.01); C12N 2795/14152 (2013.01); C12N 2799/021 (2013.01); C12N 2799/04 (2013.01); C12N 2799/06 (2013.01); C12N 2800/10 (2013.01); C12N 2810/00 (2013.01); C12N 2810/405 (2013.01); C12N 2820/10 (2013.01); C12N 2820/55 (2013.01); C12N 2820/60 (2013.01);
Abstract

The invention provides hybrid and recombinant phagemid vectors for expressing a transgene in a target cell transduced with the vector. A recombinant phagemid particle comprises at least one transgene expression cassette which encodes an agent which exerts a biological effect on the target cell, characterised in that the phagemid particle comprises a genome which lacks at least 50% of its bacteriophage genome. The invention extends to the use of such phagemid expression systems as a research tool, and for the delivery of transgenes in a variety of gene therapy applications, DNA and/or peptide vaccine delivery and imaging techniques. The invention extends to in vitro, in vivo or in situ methods for producing viral vectors, such as recombinant adeno-associated viruses (rAAV) or lentivirus vectors (rLV), and to genetic constructs used in such methods.


Find Patent Forward Citations

Loading…